Related Experiment Video
Updated: Mar 10, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Frequently Underappreciated Considerations in Anti-arrhythmic Drug Therapy.
1Department of Medicine, Division of Cardiology, Columbia University, New York, NY, USA.
Anti-arrhythmic drugs (AADs) are crucial for managing dysrhythmias but often underused due to complexities. Optimizing AAD selection and use can improve patient outcomes and drug tolerance.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Anti-arrhythmic drugs (AADs) have been central to dysrhythmia management for over a century.
- Despite advancements like ablation, AADs remain therapeutically significant for arrhythmia control.
Purpose of the Study:
- To highlight underappreciated complexities in AAD selection and use.
- To guide clinicians in optimizing AAD therapy for improved efficacy and patient tolerance.
Main Methods:
- Discussion-based review focusing on specific aspects of AAD use.
- Analysis of factors influencing AAD effectiveness and tolerability.
Main Results:
- AAD effectiveness can be limited by incomplete efficacy or adverse effects.
- Key areas for improvement include dosing, targeting therapy, selection strategies, and combination use.
Conclusions:
- Enhanced clinician awareness of AAD complexities can optimize therapeutic strategies.
- Addressing underappreciated factors in AAD use can improve patient outcomes and drug tolerance.
More Related Videos
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
08:28Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents